Applications of privacy-enhancing technology to data sharing at a global pharmaceutical company

Stephen Bamford
Additional contact information
Stephen Bamford: Head of Clinical Data Standards & Transparency, The Janssen Pharmaceutical Companies of Johnson & Johnson, UK

Journal of Data Protection & Privacy, 2020, vol. 3, issue 3, 281-290

Abstract: Janssen has been at the forefront of the recent pharmaceutical industry trend towards more transparency and sharing of clinical trials data, committing early on to make its data available for both internal and external innovation. Janssen is also committed to protecting patient privacy and giving individuals a voice on how their data is used and disclosed. This paper outlines Janssen’s data-sharing initiatives and describes how it is using leading-edge privacy-enhancing technologies (PETs) to mitigate privacy risks and find the right balance between innovation and privacy.

Keywords: privacy-enhancing technologies; data sharing; transparency; pharmaceutical industry; open data; clinical trial data (search for similar items in EconPapers)
JEL-codes: K2 (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://hstalks.com/article/5700/download/ (application/pdf)
https://hstalks.com/article/5700/ (text/html)
Requires a paid subscription for full access.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aza:jdpp00:y:2020:v:3:i:3:p:281-290

Access Statistics for this article

More articles in Journal of Data Protection & Privacy from Henry Stewart Publications
Bibliographic data for series maintained by Henry Stewart Talks ().